2023
Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms
Zyla J, Papiez A, Zhao J, Qu R, Li X, Kluger Y, Polanska J, Hatzis C, Pusztai L, Marczyk M. Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms. Computational And Structural Biotechnology Journal 2023, 21: 4663-4674. PMID: 37841335, PMCID: PMC10568495, DOI: 10.1016/j.csbj.2023.09.035.Peer-Reviewed Original ResearchSingle-cell RNA-seq platformsSingle-cell RNA sequencingBulk RNA-seq dataRNA-seq platformsNumber of transcriptsLow-expression genesRNA-seq dataSingle-cell dataExpression levelsLow sequencing depthDiscordant genesRNA sequencingSequencing technologiesExpression shiftsPathway levelBiological pathwaysGene levelSequencing depthTranscriptomic platformsGenesIndividual cellsSingle cellsRNA integrityPathwayCells
2009
Functional pathways analyses to identify candidate therapeutic targets in triple-negative breast cancer
Andre F, Dessen P, Job B, Delaloge S, Pusztai L, Lazar V. Functional pathways analyses to identify candidate therapeutic targets in triple-negative breast cancer. Journal Of Clinical Oncology 2009, 27: 569-569. DOI: 10.1200/jco.2009.27.15_suppl.569.Peer-Reviewed Original ResearchGene gainPathway analysisHigh resolution CGH arrayBRB-Array ToolsFunctional pathway analysisChromosome organizationTargetable pathwaysTriple-negative breast cancerMolecular classesGene setsCDNA arraysNotch pathwayCandidate therapeutic targetGenomic aberrationsNegative breast cancerCGH arrayHistonesPathway dysregulationPathwayGenesDifferential pathwaysVEGFA geneTherapeutic targetDysregulationHedgehog